Association of C-peptide Level with Bone Mineral Density in Type 2 Diabetes Mellitus

Overview

Journal Osteoporos Int

Specialties Endocrinology
Orthopedics

Date 2023 May 19

PMID 37204453

Authors

Hong Yang

Jia Bai

Lingling Li

Ying Yang

Yangyang Zhang

Haihong Lv

Songbo Fu

Affiliations

Soon will be listed here.

Abstract

Purpose: To explore the relationship between C-peptide and BMD and fracture risk in T2DM patients.

Methods: 530 T2DM patients were enrolled and divided into three groups by FCP tertiles, and the clinical data were collected. BMD was measured by dual-energy X-ray absorptiometry (DXA). The 10-year probability of major osteoporotic fractures (MOFs) and hip fractures (HFs) was evaluated by adjusted fracture risk assessment tool (FRAX).

Results: In the FCP ≤ 1.14 ng/ml group, FCP level was positively correlated with WB, LS, and FN BMD, while FCP was negatively correlated with fracture risk and osteoporotic fracture history. However, FCP was not correlated with BMD and fracture risk and osteoporotic fracture history in the 1.14 < FCP ≤ 1.73 ng/ml and FCP > 1.73 ng/ml groups. The study has shown that FCP was an independent factor influencing BMD and fracture risk in the FCP ≤ 1.14 ng/ml group.

Conclusions: There is no significant linear relationship between FCP level and BMD or fracture risk in T2DM patients. In the FCP ≤ 1.14 ng/ml group, FCP is positively correlated with WB, LS, and FN BMD and negatively correlated with fracture risk, and FCP is an independent influencing factor of BMD and fracture risk. The findings suggest that FCP may predict the risk of osteoporosis or fracture in some T2DM patients, which has a certain clinical value.

Citing Articles

Association between systemic immune-inflammation index and trimethylamine N-oxide levels in peripheral blood and osteoporosis in overweight and obese patients.

Li L, An J, Bai J, Zhang Y, Li X, Lv H Front Endocrinol (Lausanne). 2025; 16:1539594.

PMID: 40017693 PMC: 11864960. DOI: 10.3389/fendo.2025.1539594.

Metabolic factors are not the direct mediators of the association between type 2 diabetes and osteoporosis.

Yang Q, Wang X, Liu Y, Liu J, Zhu D Front Endocrinol (Lausanne). 2024; 15:1404747.

PMID: 39119008 PMC: 11306037. DOI: 10.3389/fendo.2024.1404747.

References

Thomas C, Philipson L . Update on diabetes classification. Med Clin North Am. 2014; 99(1):1-16. DOI: 10.1016/j.mcna.2014.08.015. View

Petersen M, Shulman G . Mechanisms of Insulin Action and Insulin Resistance. Physiol Rev. 2018; 98(4):2133-2223. PMC: 6170977. DOI: 10.1152/physrev.00063.2017. View

Leighton E, Sainsbury C, Jones G . A Practical Review of C-Peptide Testing in Diabetes. Diabetes Ther. 2017; 8(3):475-487. PMC: 5446389. DOI: 10.1007/s13300-017-0265-4. View

Jones A, Hattersley A . The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med. 2013; 30(7):803-17. PMC: 3748788. DOI: 10.1111/dme.12159. View

Hoogwerf B, Bantle J, Gaenslen H, GREENBERG B, Senske B, Francis R . Infusion of synthetic human C-peptide does not affect plasma glucose, serum insulin, or plasma glucagon in healthy subjects. Metabolism. 1986; 35(2):122-5. DOI: 10.1016/0026-0495(86)90111-3. View

Kitabchi A . The biological and immunological properties of pork and beef insulin, proinsulin, and connecting peptides. J Clin Invest. 1970; 49(5):979-87. PMC: 535770. DOI: 10.1172/JCI106317. View

Johansson B, Sjoberg S, Wahren J . The influence of human C-peptide on renal function and glucose utilization in type 1 (insulin-dependent) diabetic patients. Diabetologia. 1992; 35(2):121-8. DOI: 10.1007/BF00402543. View

Qiao X, Zheng H, Zhang S, Liu S, Xiong Q, Mao F . C-peptide is independent associated with diabetic peripheral neuropathy: a community-based study. Diabetol Metab Syndr. 2017; 9:12. PMC: 5307841. DOI: 10.1186/s13098-017-0208-2. View

Wang L, Lin P, Ma A, Zheng H, Wang K, Li W . C-Peptide Is Independently Associated with an Increased Risk of Coronary Artery Disease in T2DM Subjects: A Cross-Sectional Study. PLoS One. 2015; 10(6):e0127112. PMC: 4476669. DOI: 10.1371/journal.pone.0127112. View

10.

Panero F, Novelli G, Zucco C, Fornengo P, Perotto M, Segre O . Fasting plasma C-peptide and micro- and macrovascular complications in a large clinic-based cohort of type 1 diabetic patients. Diabetes Care. 2008; 32(2):301-5. PMC: 2628697. DOI: 10.2337/dc08-1241. View

11.

Maurotti S, Russo C, Musolino V, Nucera S, Gliozzi M, Scicchitano M . Effects of C-Peptide Replacement Therapy on Bone Microarchitecture Parameters in Streptozotocin-Diabetic Rats. Calcif Tissue Int. 2020; 107(3):266-280. DOI: 10.1007/s00223-020-00716-0. View

12.

Thrailkill K, Lumpkin Jr C, Bunn R, Kemp S, Fowlkes J . Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues. Am J Physiol Endocrinol Metab. 2005; 289(5):E735-45. PMC: 2387001. DOI: 10.1152/ajpendo.00159.2005. View

13.

Landreh M, Johansson J, Jornvall H . C-peptide: a molecule balancing insulin states in secretion and diabetes-associated depository conditions. Horm Metab Res. 2013; 45(11):769-73. DOI: 10.1055/s-0033-1347208. View

14.

Luo J, Jiang J, Huang H, Jiang F, Xu Z, Zhou Z . C-peptide ameliorates high glucose-induced podocyte dysfunction through the regulation of the Notch and TGF-β signaling pathways. Peptides. 2021; 142:170557. DOI: 10.1016/j.peptides.2021.170557. View

15.

Ferro Y, Russo C, Russo D, Gazzaruso C, Coppola A, Gallotti P . Association between low C-peptide and fragility fractures in postmenopausal women without diabetes. J Endocrinol Invest. 2017; 40(10):1091-1098. DOI: 10.1007/s40618-017-0672-4. View

16.

Zhang M, Sheng C, You H, Cai M, Gao J, Cheng X . Comparing the bone mineral density among male patients with latent autoimmune diabetes and classical type 1 and type 2 diabetes, and exploring risk factors for osteoporosis. J Endocrinol Invest. 2021; 44(8):1659-1665. DOI: 10.1007/s40618-020-01472-6. View

17.

Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Yano S, Sugimoto T . Serum osteocalcin/bone-specific alkaline phosphatase ratio is a predictor for the presence of vertebral fractures in men with type 2 diabetes. Calcif Tissue Int. 2009; 85(3):228-34. DOI: 10.1007/s00223-009-9272-4. View

18.

Liu J, Zhu D, Mu Y, Xia W . Management of fracture risk in patients with diabetes-Chinese Expert Consensus. J Diabetes. 2019; 11(11):906-919. DOI: 10.1111/1753-0407.12962. View

19.

Wen Z, Ding N, Chen R, Liu S, Wang Q, Sheng Z . Comparison of methods to improve fracture risk assessment in chinese diabetic postmenopausal women: a case-control study. Endocrine. 2021; 73(1):209-216. DOI: 10.1007/s12020-021-02724-y. View

20.

Paschou S, Dede A, Anagnostis P, Vryonidou A, Morganstein D, Goulis D . Type 2 Diabetes and Osteoporosis: A Guide to Optimal Management. J Clin Endocrinol Metab. 2017; 102(10):3621-3634. DOI: 10.1210/jc.2017-00042. View